TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:55
AMARIN CORP PLCUK ( AMRN ) https://www.amarincorp.com
0.45USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-50.14%
AMRN
SPY
32.66%
-86.84%
AMRN
SPY
108.59%
-97.92%
AMRN
SPY
302.52%
-53.79%
AMRN
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
184.48
-111.10
1.69
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.68
0.76
0.35
-7.87
0.00
1.81
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-60.14
38.89
-29.56
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.0912
-14.92
-10.75
1.84
Other Earnings and Cash Flow Stats:
AMARIN CORP PLCUK ( AMRN ) Net Income TTM ($MM) is -39.40
AMARIN CORP PLCUK ( AMRN ) Operating Income TTM ($MM) is -43.92
AMARIN CORP PLCUK ( AMRN ) Owners' Earnings Annual ($MM) is 0.00
AMARIN CORP PLCUK ( AMRN ) Current Price to Owners' Earnings ratio is 0.00
AMARIN CORP PLCUK ( AMRN ) EBITDA TTM ($MM) is -40.91
AMARIN CORP PLCUK ( AMRN ) EBITDA Margin is -29.56%
Capital Allocation:
AMARIN CORP PLCUK ( AMRN ) has paid 0.00 dividends per share and bought back -2.733 million shares in the past 12 months
AMARIN CORP PLCUK ( AMRN ) has reduced its debt by 0.713 million USD in the last 12 months
Capital Structure:
AMARIN CORP PLCUK ( AMRN ) Interest-bearing Debt ($MM) as of last quarter is 10
AMARIN CORP PLCUK ( AMRN ) Annual Working Capital Investments ($MM) are -20
AMARIN CORP PLCUK ( AMRN ) Book Value ($MM) as of last quarter is 531
AMARIN CORP PLCUK ( AMRN ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
AMARIN CORP PLCUK ( AMRN ) has 156 million in cash on hand as of last quarter
AMARIN CORP PLCUK ( AMRN ) has 201 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AMARIN CORP PLCUK ( AMRN ) has 411 common shares outstanding as of last quarter
AMARIN CORP PLCUK ( AMRN ) has 0 million USD of preferred stock value
Academic Scores:
AMARIN CORP PLCUK ( AMRN ) Altman Z-Score is -1.81 as of last quarter
AMARIN CORP PLCUK ( AMRN ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
AMARIN CORP PLCUK ( AMRN ) largest shareholder is owning shares at 0.00 ($MM) value
Berg Aaron(an insider) Bought 160000 shares of AMARIN CORP PLCUK ( AMRN ) for the amount of $102400.00 on 2024-08-02
1.59% of AMARIN CORP PLCUK ( AMRN ) is held by insiders, and 19.72% is held by institutions
AMARIN CORP PLCUK ( AMRN ) went public on 1993-04-01
Other AMARIN CORP PLCUK ( AMRN ) financial metrics:
FCF:-19.39
Unlevered Free Cash Flow:0.00
EPS:-0.24
Operating Margin:-60.14
Gross Profit Margin:38.89
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-18.92
Beta:1.84
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AMARIN CORP PLCUK ( AMRN ) :
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a preion-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.